Time to initial highly active antiretroviral therapy discontinuation and its predictors among HIV patients in Felege Hiwot comprehensive specialized hospital: a retrospective cohort study

Table 2 Baseline clinical, laboratory and ART information of HIV positive patients, at Felege Hiwot comprehensive specialized hospital from January 1, 2014 to December 2019

Variables	Category	Frequency	Percentage (%)
Initial regimen	TDF-3TC-EFV^a	264	63.2
	TDF-3TC-NVP^b	8	1.9
	AZT-3TC-EFV^c	72	17.2
	AZT-3TC-NVP^d	56	13.4
	ABC-3TC-EFV^e	18	4.3
Number of ART pills	One pill/day	311	74.4
Number of ART pills	> one pill/day	107	25.6
Functional status	Working	362	86.6
	Ambulatory	41	9.8
	Bedridden	15	3.6
Baseline WHO clinical stage	I	186	44.5
	II	77	18.4
	III	76	18.2
	IV	79	18.9
Baseline CD4 count	< 100 cells/mm³	88	21
	100–199 cells/mm³	78	18.7
	200–349 cells/mm³	97	23.2
	> = 350 cells/mm³	155	37.1
Adherence	Good	353	84.4
	Fair	32	7.7
	Poor	33	7.9
Past OI	Yes	36	8.6
Past OI	No	382	91.4
CPT prophylaxis	Yes	222	53.1
CPT prophylaxis	No	196	46.9
Baseline hemoglobin	< 7 g/dl	1	0.2
	7–9.9 g/dl	13	3.1
	10–12.9 g/dl	97	23.2
	≥ 13 g/dl	307	73.4
Viral load	< 1000 copies/ml	366	87.6
Viral load	> = 1000 copies/ml	52	12.4
TB infection	Yes	83	19.9
TB infection	No	335	80.1
Co-medication	Yes	120	28.7
Co-medication	No	298	71.3

ISSN: 1742-6405